Olga Danilova, M.D., Ph.D.

(877) 541-4673
Olga Danilova, M.D., Ph.D.
Pathologist
Clinical Expertise
  • Hematopathology
Other Languages Spoken
Russian
Academic Appointments
  • Associate Clinical Professor, Department of Pathology
Clinical Teams
Pathology

Olga Danilova, M.D., Ph.D., graduated summa cum laude from Yaroslavl Medical Academy in Russia, where she also completed graduate studies in pharmacology. Dr. Danilova joined the molecular pathology laboratory at Tufts University School of Medicine in 2003, where she developed a research interest in lymphoid malignancies. Her studies have focused on the development of prognostic markers and novel therapies in chronic lymphocytic leukemia and lymphoma, with special emphasis on bench-to-bedside translation.

Dr. Danilova further pursued her clinical career at Dartmouth Hitchcock Medical center where she completed residency in anatomic and clinical pathology in 2013 and hematopathology fellowship in 2014. Between 2014 and 2020, she served as a hematopathologist and medical director of hematology and transfusion services at Portland VA Health Care System. Her translational research efforts resulted in multiple collaborative publications and educational book chapters and reviews. Dr. Danilova is excited to join the world renowned team of experts at City of Hope®.

Location

Education & Experience

Board Certifications

  • 2014–2024, Hematopathology (certificate #S-14-319)
  • 2013–2023, Anatomical/Clinical pathology (certificate #13-607)

Degrees

  • 2003–2009, Postdoctoral Associate, Tufts University School of Medicine, Boston, MA
  • 2000–2003, Doctor of Philosophy (Ph.D.), Pharmacology (Thesis: “Pharmacologic effects of beta-adrenoblockers on vasoactive molecules in chronic heart failure”), Yaroslavl Medical Academy, Russia
  • 1994–2000, Doctor of Medicine (M.D.), Yaroslavl Medical Academy, Russia

Fellowship

  • 2013–2014, Hematopathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Residency

  • 2009–2013, Pathology AP/CP, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Professional Experience

  • 2020–present, Assistant Clinical Professor, Department of Pathology, City of Hope, Duarte, CA
  • 2015–present, Staff Hematopathologist/Pathologist, Medical Director of Hematology and Transfusion Medicine, Pathology and Laboratory Medicine, VA Portland Health Care System, affiliate assistant professor, Pathology & Lab Medicine, OHSU
  • 2014–2015, Consulting/Attending physician, Medical Director of Hematology and Transfusion Medicine, Pathology and Laboratory Medicine, VA Portland Health Care System

Awards & Memberships

Awards

  • 2007, Winner, BD Biosciences 2007 Research Grant Program “A New Prognostic Factor and Potential Treatment of Chronic Lymphocytic Leukemia (CLL)”
  • 2002, Winner, National Contest of Young Investigators “Regulation of stress mediators by beta-adrenoblockers in chronic heart failure”
  • 2001, Travel award for the participation in the 5th Congress of the European Association of Clinical Pharmacology and Therapeutics, Denmark, 2001
  • 1993, Finalist of the student exchange educational program of USA FSA

Memberships

  • 2014–present, member, Society for Hematopathology
  • 2009–present, member, College of American Pathologists
  • 2009–2015, member, American Society for Clinical Pathology
  • 2009–2015, member, United States & Canadian Academy of Pathology

Publications

  • Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, Spurgeon SE, Danilova OV, Danilov AV. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017 Nov;102(11):1890-1900. DOI:10.3324/haematol.2017.170571.
  • Paiva C, Godbersen JC, Rowland T, Danilova OV, Danes C, Berger A, Danilov AV. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. Oncotarget, 2017; 8(13):21128-21139
  • Gordon MJ, Danilova O, Spurgeon S., Danilov AV. Cardiac non-Hodgkin’s lymphoma: clinical characteristics and trends in survival. Europ J of Hem, 2016; 97(5): 445-452.
  • Danilova OV, Danilov AV. Pericardial involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. July 15 2015; 126(3): 424.
  • Godbersen JC, Paiva C, Danilova OV, Berger A, Brown JR, Danilov AV. Targeting neddylation effectively antagonizes nuclear factor –kB in chronic lymphocytic leukemia B- cells. Leukemia & Lymphoma, May 2015; 56(5): 1566-1569.
  • Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, Danilov A. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NFκB activation and induces apoptosis in chronic lymphocytic leukemia B-cells. Clin Cancer Research; 20(6) March 2014.
  • Humphries LA, Godbersen JC, Danilova OV, Kaur P, Christensen B, Danilov AV. 2013. Pro-apoptotic p53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signaling in chronic lymphocytic leukemia. British Journal of Haematology, 2013 Dec; 163(5):590-602.
  • Danilova OV, et al. A case report of AML with myelodysplasia-related changes with aggressive course in association with t(3;8)(q26;q24). DOI: 10.1007/s12308-013-0187-7. Journal of Hematopathol, 2013 June; 6:245-251.
  • Srivastava S, Danilova OV, et al. Intracellular and extracellular immunoglobulin crystals assuming a multitude of geometric shapes in an IgG-lambda plasma cell neoplasm. American Journal of Hematology, 2013 Dec; 88(12):1094-5.
  • Danilova OV, et al. FASN and CD36 predict survival in rituximab treated Diffuse Large B- cell Lymphoma. J of Hematopathol. 2013, Mar;6(1):11-18.
  • Khagi S, Danilova O, Rauwerdink C. Hemophagocytic syndrome in a patient with human immunodeficiency virus, Epstein-Barr viremia, and newly diagnosed Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Apr; 10(4):260-2.
  • Bakhoum SF, Danilova OV, Kaur P, Levy NB, Compton DA. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2011 Dec; 17(24):7704-11.
  • Editor of Russian translation. Guidelines on the use of therapeutic apheresis in clinical practice — evidence-based approach from the apheresis applications committee of the American Society for Apheresis. Z. Szczepiorkowski et al, Journal of Clinical Apheresis. 2010; (25):83–177.
  • Danilov AV, Danilova OV (first co-authorship), Brown JR, Rabinowitz A, Klein AK, Huber BT. Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol. 2010 Dec; 38(12):1167- 77.
  • Danilova OV, et al. Neurogenin 3-Specific Dipeptidyl Peptidase-2 Deficiency Causes Impaired Glucose Tolerance, Insulin Resistance, and Visceral Obesity. Endocrinology. 2009 Dec; 150(12):5240-8.
  • Danilov AV, Pilichowska M, Danilova OV, Sprague KA. 2008. AIDS-related Burkitt Lymphoma — a Heterogeneous Disease? Leuk Res. 2008 Dec; 32(12):1939-41.
  • Danilov AV, Danilova OV, Huber BT. Cell Cycle Control And Adhesion Signaling Pathways in the Development of Metastatic Melanoma. Cancer Metastasis Rev. 2008 Dec; 27(4):707-14.
  • Danilova O, Li B, Szardenings AK, Huber BT, Rosenblum JS. Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorganic and medicinal chemistry letters. 2007; 17(2): 507-510.